a collection of information unless it contains a valid CMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)
(,

Application Number		10617452	
Filing Date		2003-07-11	
First Named Inventor Minte		eer et al.	
Art Unit		1745	
Examiner Name	Angela Martin		
Attorney Docket Number		SLU 4554.1	

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Releva Figures Appear
	1	5521101		1996-05-28	Sam et al.	
	2	6387625		2002-05-14	Eckhardt et al.	
f you wish	n to a	dd additional U.S. Pater	t citatio	n information p	lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document Pages, Columns, Lines when Relevant Passages or Releving Figures Appear	
	1	20030164335		2003-09-04	Grate et al.	
	2	20040101741		2004-05-27	Minteer et al.	
	3	20040121018		2004-06-24	Grate et al.	
	_					

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10617452
Filing Date		2003-07-11
First Named Inventor Minte		er et al.
Art Unit		1745
Examiner Name	Ange	la Martin
Attorney Docket Numb	er	SLU 4554.1

Examiner Initial*	Cite No	Foreign Di Number ³	ocument	Country Code ² į	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1	200407984	18	wo	A	2004-09-16	Yissum Research Development Company of the Hebrew		
	2	0300082		EP	A	1989-01-25	Bridgestone Corporation		
If you wis	h to a	dd additiona	I Foreign P				lease click the Add butto		
				NON-PATER	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*						Ţ5			
	1	CHEN et. at. "A ministure biofuel cell" Journal of American Chemical Society, 123: 9630-9631 (2001).							
	2 Kilf et al. "A ministure membrane-less biofuel cell operating under physiological conditions at 0.5V" Journal of Electrochemical Society, 150(2): A09-A213 (2003).								
	LEONIDA et al., "Co-electropolymerization of a viologen oligomer and lipoamide dehydrogenase on an electrode surface. Application to cofector regeneration? Bioceganic & Medicinal Chieristry Letters, Oxford, GB, 8(14): 1685-1686 (1998).								
	Partial Search Report for analogous PCT Application No. PCT/US04037151 dated May 26, 2006.								
If you wis	h to a	dd additiona	al non-pater	nt literature docu	ment cit	tation informat	ion please click the Add	button Add	
				EX	AMINE	R SIGNATUR	E		
Examiner	Signa	iture					Date Considered		
"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10617452
	Filing Date		2003-07-11
	First Named Inventor Minte		er et al.
	Art Unit		1745
	Examiner Name	Ange	la Martin
	Attorney Docket Numb	er	SLU 4554.1

See four Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. * Exister office in all assets for electrons, by the loss letter code (WPO) Standard 51.3. * *Projectioned projection pr

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10617452
Filing Date		2003-07-11
First Named Inventor Minte		er et al.
Art Unit		1745
Examiner Name	Ange	la Martin
Attorney Docket Numb	er	SLU 4554.1

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate	selection(s):
---------------	----------	------------------	-----------------	---------------

	That each item of information contained in the information disclosure statement was first cited in any communication
	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(eV1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c)

_	See attached	cortification	etatement

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Janet S. Hendrickson, Ph.D./	Date (YYYY-MM-DD)	2006-06-28
Name/Print	Janet S. Hendrickson, Ph.D.	Registration Number	55 258

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.